Ascentage Pharma…
USUSDAscentage Pharma Group International (US:AAPG) — Biotechnology: Pharmaceutical Preparations. Nombre de places boursières sur lesquelles les actions de la société sont cotées : 1. Sur cette page : cours et graphique, dividendes, principaux actionnaires et historique du nombre d'actions.
À propos de l'entreprise
- Site Web
- ascentage.cn
- Relations avec les Investisseurs
- ascentage.cn/investor-relations/
- Secteur
- Health Care · Biotechnology: Pharmaceutical Preparations
- Siège Social
- SUZHOU , JIANGSU, China
- Direction
- Dajun Yang
- Employés
- 828
- IPO
- 2019-10-28
- Actions en Circulation
- 373.32 M au 2026-04-01
- Flottant
- 71.53 M
- Capitalisation Boursière
- 10.71 Md CNY
- Initiés
- 0%
- Investisseurs Institutionnels
- 0.04%
- Secteur d'Activité (SIC)
- Pharmaceutical Preparations
Description
Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company's primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation. It also develops APG-2575, an oral administered Bcl-2 selective inhibitor for hematologic malignancies and solid tumors; APG-115, an oral small molecule inhibitor of the MDM2-p53 protein-protein interactions to treat solid tumors and hematological malignancies; and APG-1252, a small molecule drug to restore apoptosis through dual inhibition of the Bcl-2 and Bcl-xL proteins for the treatment of small-cell lung cancer, non-small cell lung cancer, neuroendocrine tumor, and non-Hodgkin's lymphoma. In addition, the company is developing APG-1387, a small-molecule inhibitor of apoptosis proteins for advanced solid tumors and chronic HBV infection; APG-5918, an orally available and selective embryonic ectoderm development inhibitor. In addition, it is involved in medical research and development; clinical development; clinical trials operations; venture capital investment; rental of buildings; and provision of science and technology promotion services. The company has strategic partnership with biotechnology and pharmaceutical companies; research institutions; and Peking University to build a collaborative system for hematological oncology. Ascentage Pharma Group International was founded in 2009 and is headquartered in Suzhou, China.
Bourses et Tickers
| Bourse | Ticker | Devise | Prix | Type |
|---|---|---|---|---|
| US USA Stocks | AAPG | USD | 14.88 -0.70% | actions ordinaires |
Principaux Actionnaires
| Détenteur | Participation | Actions | Date du Rapport |
|---|---|---|---|
| Point72 Asset Management… | 0.01% | 13 841 | 2026-06-30 |
| Fidelity Concord Street… | 0% | 1 558 | 2026-08-31 |
| Morgan Stanley | 0% | 919 | 2026-06-30 |
| Wells Fargo & Company | 0% | 200 | 2026-06-30 |
| Eversource Wealth Adviso… | 0% | 24 | 2026-06-30 |
| UBS Group AG | 0% | 15 | 2026-06-30 |
| Blackrock Inc. | 0% | 6 | 2026-06-30 |
| Royal Bank of Canada | 0% | 6 | 2026-06-30 |
| Nisa Investment Advisors… | 0% | 5 | 2026-09-30 |
| Caitong International As… | 0% | 1 | 2026-06-30 |
